New hope for advanced lung cancer: atamparib trial launches
NCT ID NCT07374419
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests an experimental drug, atamparib, in people with advanced non-small cell lung cancer (a common type of lung cancer) that has spread and stopped responding to standard treatments. The trial has two parts: first, finding the safest dose, then testing how well it works in a larger group. About 178 adults with a specific gene change (KRAS mutation) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.